A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

Trial Profile

A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

Suspended
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Nivolumab (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Sep 2017 According to a Bristol-Myers Squibb media release, the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on this trial because of risks identified in trials studying another anti PD1 agent, pembrolizumab, in patients with multiple myeloma.
    • 06 Sep 2017 Status changed from active, no longer recruiting to suspended, according to a Bristol-Myers Squibb media release.
    • 05 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top